Results 11 to 20 of about 3,975 (165)

Effect of ABCB1 most frequent polymorphisms on the accumulation of bictegravir in recombinant HEK293 cell lines

Scientific Reports
Bictegravir, a key second-generation integrase strand transfer inhibitor in the treatment of HIV, is subject to active efflux transport mediated by ABCB1 (P-glycoprotein).
Julien De Greef, Mathilde Akue, Nadtha Panin, Kévin-Alexandre Delongie, Marina André, Gwenaëlle Mahieu, Emilia Hoste, Laure Elens, Leïla Belkhir, Vincent Haufroid   +9 more
doaj   +2 more sources

A New Combined Antiretroviral Therapy In Adolescents With HIV: Bictegravir/Emtricitabine/Tenofovir Alafenamide

Journal of Global Antimicrobial Resistance
AIM: We aimed to evaluate the treatment response and side effect profile of bictegravir as initial therapy in HIV-naive adolescents. BACKGROUND: Bictegravir is a potent integrase helicase transfer inhibitor with a high genetic barrier to resistance ...
Neslihan Mete Atasever, Elif Dede, Öznur Bulut, Ayper Somer, Selda Hançerli Törün   +4 more
doaj   +2 more sources

Exploring the pharmacokinetic mechanisms that affect bictegravir exposure during pregnancy. [PDF]

J Antimicrob Chemother
Contains fulltext : 331974.pdf (Publisher’s version ) (Open Access)INTRODUCTION: Pregnancy is associated with physiological changes, resulting in altered pharmacokinetics, which may impact antiretroviral drug exposure.
van der Wekken-Pas L, Hidalgo-Tenorio C, Rockstroh JK, van Bremen K, Richel O, Molto J, Lambert JS, de Kanter C, Konopnicki D, Burger D, Colbers A.   +10 more
europepmc   +2 more sources

Bictegravir/emtricitabine/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational BICSTaR cohort

HIV Research & Clinical Practice
Background: BICtegravir Single Tablet Regimen (BICSTaR) is an observational cohort study evaluating the effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve (TN) and treatment-experienced (TE) people ...
Benoit Trottier, Chia-Jui Yang, Dai Watanabe, Giulia Marchetti, Daniel Elbirt, Eoghan De Barra, Alper Gündüz, Sun Hee Lee, Roger Vogelmann, Olivier Robineau, Chiaw Yee Choy, Marvin Berrevoets, Alison Uriel, David Thorpe, Marion Heinzkill, Andrea Marongiu, Johanna Ramroth, Lisa D’Amato, Josep Mallolas   +18 more
doaj   +3 more sources

Physiologically‐Based Pharmacokinetic Modeling to Support the Clinical Management of Drug–Drug Interactions With Bictegravir [PDF]

, 2021
Bictegravir is equally metabolized by cytochrome P450 (CYP)3A and uridine diphosphate-glucuronosyltransferase (UGT)1A1. Drug–drug interaction (DDI) studies were only conducted for strong inhibitors and inducers, leading to some uncertainty whether ...
Marzolini, C., Marzolini, C, Felix Stader, Battegay, M., Catia Marzolini, Stader, F., Battegay, M, Stader, F, Manuel Battegay   +8 more
core   +1 more source

Population Pharmacokinetics of Bictegravir During Pregnancy and Postpartum: Role of Adherence in Maintaining Therapeutic Exposure [PDF]

Journal of Clinical Pharmacology
Mina Nikanjam, Edmund Capparelli, Jeremiah Momper   +2 more
exaly   +2 more sources

Antiretroviral drugs efavirenz, dolutegravir and bictegravir dysregulate blood-brain barrier integrity and function

Frontiers in Pharmacology, 2023
The implementation of combined antiretroviral therapy (cART) significantly reduces the mortality associated with human immunodeficiency virus (HIV) infection.
Chang Huang, Tozammel Hoque, Reina Bendayan   +2 more
doaj   +1 more source

Physiologically‐Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV [PDF]

, 2021
Clinical studies in aging people living with HIV (PLWH) are sparse for the novel integrase inhibitor bictegravir, leading to some uncertainty about dosing recommendations for elderly PLWH.
Decosterd, L.A., Perrine Courlet, Catia Marzolini, Stader, F., Courlet, P, Manuel Battegay, Marzolini, C., Marzolini, C, Felix Stader, Decosterd, LA, Battegay, M., Courlet, P., Battegay, M, Stader, F, Laurent A. Decosterd   +14 more
core   +1 more source

Assessment of Gastrointestinal Adverse Effects during the First Six Months of “Biktarvy” Antiretroviral Therapy: Age-Related Patterns and Their Relation with Changes of 5 kg Weight Loss/Gain in the Initial Treatment Period

Diseases, 2023
Background: The battle against HIV has led to the development of antiretroviral therapy (ART), including BIKTARVY®, which combines three potent agents.
Madalina-Ianca Suba, Simona-Alina Abu-Awwad, Ovidiu Rosca, Mirela-Mădălina Turaiche, Bogdan Hogea, Ahmed Abu-Awwad, Razvan Nitu, Voichita Elena Lazureanu   +7 more
doaj   +1 more source

Population pharmacokinetics of bictegravir in real-world people with HIV. [PDF]

J Antimicrob Chemother
Bictegravir is an integrase strand transfer inhibitor widely prescribed due to its good efficacy and safety profile. Its pharmacokinetic (PK) profile has not been described in real-world settings yet.
Ekobena P, Briki M, Dao K, Marzolini C, Andre P, Buclin T, Cavassini M, Guidi M, Thoueille P, Swiss HIV Cohort Study .   +9 more
europepmc   +2 more sources